[5] However, 20% of ITP patients fail to achieve a response to c‐Mpl agonists, and most patients rapidly experience relapse and lose their sensitivity to c‐Mpl agonists after drug discontinuation.[8, 9] The failure mechanism of c‐Mpl agonists urgently needs to be clarified. This evidence concerns the gene MPL and autoimmune thrombocytopenic purpura.